US Edition
News from Pharmacy Times
We’ve assigned a rating of Unknown factuality to Pharmacy Times. You can read more about how we’ve determined Pharmacy Times’s credibility and reliability as a news source here: https://ground.news/rating-system.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Pharmacy Times News
United States · United StatesNovel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegalySee the Story
Crinetics Announces FDA Approval of PALSONIFY™ (Paltusotine) for the Treatment of Adults with ...
Coverage: 14 sources
FDA · United States(MedPage Today) -- The FDA approved lurbinectedin (Zepzelca) plus either atezolizumab (Tecentriq) or atezolizumab and hyaluronidase (Tecentriq Hybreza) as first-line maintenance therapy for extensive-stage small cell lung cancer, the agency announced...See the Story
FDA Approves Maintenance Combo for Small Cell Lung Cancer
80% Center coverage: 5 sources
Mifepristone · United StatesThe anti-abortion movement’s patience with the Food and Drug Administration (FDA) is wearing thin following the agency’s recent approval of a second generic version of mifepristone, one of two drugs taken for a medication abortion. President Trump repeatedly pledged during the campaign last year that he would leave abortion policy to the states, but…See the Story
FDA Under Pressure From Right After Abortion Pill Approval
67% Center coverage: 3 sources
